Arca
Skip to content

Essential thrombocythemia

Drug research and approvals for essential thrombocythemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 49 studies of essential thrombocythemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 10 drug trials for it since 2013, and FDA has 7 approved and 6 open orphan designations naming it.

  • Recruiting worldwide: 49
  • Trials authorized in Canada: 10
  • FDA orphan approvals: 7
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 49 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Jul 23, 2026A phase 3, randomized, open-label study of inca033989 versus best available therapy in participants with essential thrombocythemia and a calr mutation…INCA033989Incyte CorporationOngoing
Jul 12, 2024A phase 3, randomized, double-blind, active-comparator-controlled clinical study to evaluate the efficacy and safety of bomedemstat (mk-3543) versus…BOMEDEMSTAT (MK-3543) / HYDROXYUREAMerck & Co. (MSD)Ongoing
Dec 21, 2023A phase 3, randomized, open-label, active-comparator-controlled clinical study to evaluate the safety and efficacy of bomedemstat (mk-3543/img-7289) versus…BOMEDEMSTAT (MK-3543, IMG-7289)/ BUSULFANMerck & Co. (MSD)Ongoing
Sep 2, 2022A single-arm, multicenter study to assess the efficacy, safety, and tolerability of ropeginterferon alfa-2b-ajft (p1101) in adult patients with essential…ROPEGINTERFERON ALFA-2B-NJFT (P1101)PharmaEssentiaOngoing
Jul 2, 2021A phase 3, open-label, multicenter, randomized, active-controlled study to assess pharmacokinetics and compare the efficacy, safety, and tolerability of p1101…P1101PharmaEssentiaOngoing
Nov 29, 2019A randomized, controlled phase 3 study of pacritinib versus physician's choice in patients with primary myelofibrosis, post polycythemia vera myelofibrosis, or…PACRITINIB (SB1518) / RUXOLITINIB / HYDROXYUREA / DANAZOLSobiOngoing
Feb 28, 2018Extended access of momelotinib for subjects with primary myelofibrosis (pmf) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis…MOMELOTINIBGSKClosed
Jan 10, 2017A multicenter phase II, open label, single arm study to evaluate the efficacy and safety of ruxolitinib in the treatment of anemic myelofibrosis patients.JAKAVI (INC424, RUXOLITINIB)Novartis Pharmaceuticals CorporationClosed
May 9, 2014A randomized controlled phase 3 study of oral pacritinib versus best available therapy in patients with thrombocytopenia and primary myelofibrosis,…PACRITINIB (SB1518)CTI BIOPHARMA CORPOngoing
Feb 6, 2014A phase 3, randomized, double-blind active-controlled study evaluating momelotinib vs. ruxolitinib in subjects with primary myelofibrosis (pmf) or…MOMELOTINIBGilead SciencesClosed

FDA Orphan Designations

Approved first, then open designations, newest first
Aug 28, 2026Besremitreatment of adults with essential thrombocythemiaPharmaEssentiaApproved
May 1, 2026Jakafi XRtreatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential…Incyte CorporationApproved
Sep 15, 2023Ojjaaratreatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and…GlaxoSmithKlineApproved
Feb 28, 2022VonjoTreatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia)…Sobi, Inc.Approved
Aug 16, 2019INREBICINREBIC® is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or…Impact Biomedicines, Inc. a wholly-owned subsidiary of Celgene CorporationApproved
Nov 16, 2011JakafiTreatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis…Incyte CorporationApproved
Mar 14, 1997AgrylinTreatment of patients with essential thrombocythemia to reduce the elevated platelet count and the risk of thrombosis and to ameliorate…Takeda Development Center Americas, Inc.Approved
Nov 2, 2026humanized IgG1 bispecific antibody binding to CD3 and…treatment of essential thrombocythemiaJanssen Research & Development, LLCDesignated
Jan 1, 2026recombinant fully human IgG1 monoclonal antibody…treatment of essential thrombocythemiamAbTree Biologics AGDesignated
Jun 27, 2024peginterferon alfa-2aTreatment of essential thrombocythemia (ET)Pharma& U.S. Inc.Designated
Dec 14, 2020Jaktinib Dihydrochloride MonohydrateTreatment of Primary Myelofibrosis (PMF) or Post-polycythemia Vera/Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)Suzhou Zelgen Biopharmaceuticals Co., Ltd.Designated
Nov 7, 2018bomedemstatTreatment of essential thrombocythemia.Merck & Co., Inc.Designated
Mar 22, 2010ruxolitinib phosphateTreatment of essential thrombocythemiaIncyte CorporationDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.